Bio Expo Online / Process Services / Optical resolution
Aarti Industries, Ltd.
We have capability of building a manufacturing plant as per the need of the customer in a relatively short time, by maintaining regulatory standards of SHE.
Aesica Pharmaceuticals Limited
Our state-of-the-art technology offers the capability to manufacture development compounds in quantities for use in Phase I to III clinical trials or for high volume continuous supplies. We will carry out all your IND/CMC requirements from the preclinical stage right through to commercial supply.
Arran Chemical Company
The BioVerdant team has pioneered and developed automated systems for high throughput enzyme and microbial screening. Our enzyme discovery capabilities and state-of-the-art protein engineering are utilized to fully explore a wide variety of enzyme catalyzed reactions. In addition to producing significant cost savings and new intellectual property, our Green Chemistry approach to chemical manufacturing is ideal for minimizing the effects of organic waste products on the environment.
Chemagis USA, Inc
Operating two modern state of the art cGMP manufacturing facilities having been successfully inspected by numerous global regulatory authorities including the FDA, ChemAgis has the capability, infrastructure and expertise to comply and deliver on any given project. We welcome the opportunity to entertain your inquiry under agreement of confidentiality.
Daiso Co., Ltd.
Digital Specialty Chemicals, Inc.
Dishman group subsidiary, Synprotec DCR conducts contract Research and production of non GMP intermediates. IO3S is another Dishmangroup company that specializes in ozonolysis for process R&D and full-scale production.
Pharmaceutical and fine chemicals companies can contract Dowpharma to manufacture chiral intermediates in either cGMP or non-cGMP assets using its proprietary technology, or directly purchase catalysts and operate the process in the facilities of their choice. In addition, Dowpharma can offer products produced through its preferred Asian contract manufacturing network.
Formosa Laboratories, Inc.
Mitsui Chemicals America, Inc.
Novasep Synthesis provides R&D and custom synthesis, from lab to industrial scale, with special expertise in hazardous chemistry , chiral chemistry ,and Highly Potent APIs. This network includes Dynamit Nobel, Finorga, and Séripharm.
Park Place Research
PCI Synthesis has the proven ability to navigate the regulatory processes. The company is harmonized to the ICH guidelines and is Part 11 7a compliant.
PII Pharmaceutics International Inc.
Regis Technologies, Inc.
In 2006, Regis opened a new synthetic laboratory wing, doubling the R&D capacity. Regis recently added a Supercritical Fluid Chromatography (SFC) Preparative Separations group, which will be open for GMP projects at the end of first quarter in 2007. Regis also holds proprietary Pirkle type chiral technology. Regis has completed multiple validations and is the approved commercial manufacturer of several drug substances.
Sinochem Jiangsu Corporation
Solvay Organics GmbH